Regeneron (REGN) Q3 2026 Earnings Call Transcript

Regeneron reported Q3 2026 earnings, with total revenue up 36% and non-GAAP EPS up 70% YoY. Key drugs Dupixent, EYLEA HD, and Libtayo set sales records. Dupixent global sales reached $6.5B, EYLEA HD U.S. sales hit $700M, and Libtayo global sales were $550M. The company highlighted pipeline progress in neuromuscular, metabolic, and oncology areas, with potential blockbuster opportunities.

Original reporting
Published Oct 30, 2026, 3:29 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 30, 2026, 3:40 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Regeneron (REGN) Q3 2026 Earnings Call Transcript — source image
Decision brief

The 30-second read

$REGNBullishMed
01

Why it matters

The call combines quantified earnings growth with multiple time-bound catalysts (FDA decision timing and planned study starts), which can change near-term expectations for revenue durability and risk-adjusted pipeline value.

02

Market read

Traders can use the disclosed Q3 growth figures and the stated November FDA decision and planned registrational steps to reassess near-term catalyst calendars and probability-weighted pipeline value.

03

What to watch

Key valuation swing factors are the probability and timing of regulatory outcomes (cemdisiran FDA decision in November) and the success of planned potentially registrational/confirmatory studies, which are not quantified in the excerpt.

Relevance 7/10Novelty 6/10Timing: during/after the Q3 2026 earnings call (same day)

Background

This is a transcript of Regeneron’s Q3 2026 earnings call, covering commercial performance, pipeline updates, and business development commentary.

Company-level read

Ticker impact

$REGNBullishMedium confidence
Context

Regeneron reports Q3 results with revenue up 36% and non-GAAP EPS up 70%, plus pipeline catalysts including an FDA decision expected in November for cemdisiran.

Expected impact

Likely upward bias as the market prices in strong commercial momentum and increased probability-weighted value from upcoming regulatory and registrational milestones.

Evidence & confidence

The transcript provides concrete Q3 performance figures and specific upcoming catalysts (FDA decision timing, planned pivotal/confirmatory studies), which can drive near-term repricing versus a baseline earnings-only narrative.

Market effects

Reinforces positive sentiment for large-cap biotech commercial execution and late-stage pipeline execution, particularly in immunology, ophthalmology, and oncology.

Primarily US biotech sentiment; could modestly influence broader healthcare risk appetite around earnings season.

Global sales commentary (e.g., Dupixent and EYLEA HD) may affect international biotech sentiment but is not a cross-border policy shock.

Counterpoint

Strong reported growth may be partially driven by partner commercialization dynamics (e.g., Sanofi for Dupixent/EYLEA HD), so investors may discount the durability of REGN’s earnings power versus pipeline execution risk.

Key entities

  • Regeneron Pharmaceuticals

    US-listed biotech reporting Q3 2026 results and providing pipeline and regulatory timing updates.

  • Sanofi

    Partner cited for Dupixent and EYLEA HD sales and commercialization responsibilities in an expanded alliance.

  • cemdisiran

    siRNA therapy in generalized myasthenia gravis with an FDA decision expected in November.

  • Libtayo

    Oncology immunotherapy discussed with record sales and long-term Phase III c-POST data presentation.

  • ubamatamab

    MUC16xCD3 bispecific antibody with encouraging data in advanced low grade serous ovarian carcinoma.

Related articles

$LLYMedAI 8/10

Rx Rundown: Ollin Biosciences, AstraZeneca, Isomorphic Labs and more

Eli Lilly, AbbVie, Johnson & Johnson, and others announced major deals and acquisitions in the biopharma sector, totaling billions. AstraZeneca, Roche, and Novo Nordisk received FDA approvals for new treatments. Isomorphic Labs raised $5 billion in private financing. AstraZeneca cut 600 jobs, while Cellectis plans to cut 70% of its workforce.

$REGNHigh

Argus raises Regeneron stock price target on Dupixent strength

Argus raised its price target for Regeneron (REGN) to $1,050, citing strong growth in Dupixent sales, which rose 35% to $6.54B in Q3 2026. REGN's revenue grew 19% YoY, with analysts revising earnings estimates upward. The company's partnership with Sanofi now generates more revenue than its Eylea franchise. Other drugs like Libtayo and Praluent also showed significant sales growth. REGN's pipeline includes cenvacibart, with estimated peak sales of $2B-$4B if approved.

$SNYMed

Sanofi and Regeneron’s rare disease wins; Lilly’s dealmaking dance

Sanofi received FDA approval for Infilbray, the first treatment for neurological symptoms of type 3 Gaucher disease. Regeneron's Livsayis, for generalized myasthenia gravis, also gained approval but faces competition. Eli Lilly announced two cancer-focused deals: a $5.9B research agreement with Stipple Bio and a $1.5B acquisition of Calytrix Bio. Lilly's weight loss drugs face new FDA safety warnings.

$REGNMed

EC Approves Extended Cemiplimab Dosing in Skin, Lung, and Cervical Cancers

The European Commission approved an extended dosing schedule for cemiplimab (Libtayo), a cancer drug by Regeneron Pharmaceuticals, across all approved indications in skin, lung, and cervical cancers. The new schedule allows 700 mg every 6 weeks after 12 weeks of 350 mg every 3 weeks, with shorter infusion times. The decision follows a positive opinion from the European Medicines Agency. According to Regeneron, this aims to reduce patient burden and increase healthcare flexibility.

$REGNMed

FDA Approves First siRNA Therapy for AChR-Positive Myasthenia Gravis

Regeneron's Cemdisiran (Livsayis) received FDA approval for treating AChR-positive generalized myasthenia gravis (gMG). The siRNA therapy, dosed quarterly, showed significant improvements in clinical trials. Regeneron estimates 85,000 US patients may benefit. The therapy carries a boxed warning for meningococcal infections. Regeneron did not disclose launch date or pricing.

$REGNMed

REGN Gets FDA Nod for Livsayis in Generalized Myasthenia Gravis

Regeneron Pharmaceuticals received FDA approval for Livsayis, a siRNA therapy for generalized myasthenia gravis (gMG). It is the first of its kind and is administered subcutaneously four times a year. The approval was based on positive phase III NIMBLE study results, showing significant symptom improvement. Livsayis carries a Boxed Warning for serious infections. Regeneron's stock has risen 22.9% year-to-date. The therapy is under review in the EU and planned for other regions.